Monteverde & Associates investigates four mergers for potential shareholder claims

M&A · Partnership
โดย GlobeNewswire·US·Read original
Summary · why it matters

Monteverde & Associates PC is investigating four proposed acquisitions for potential breaches of fiduciary duty and other violations of law. The firm is examining the sale of Forte Biosciences to argenx BV at $77.00 per share in cash, Luxfer Holdings to affiliates of Wynnchurch Capital at $17.37 per share in cash, Sanara MedTech to MiMedx Group for $33.00 in cash and 0.4735 shares of MiMedx common stock per Sanara share, and MarketAxess Holdings to Intercontinental Exchange at $167.00 per share in cash. Shareholders are encouraged to contact the firm before the applicable tender offer deadlines, including August 26, 2026 for Forte Biosciences.

Impact on stocks 8

Biotech & Genomic Medicine▲ · 2 stocks
MiMedx Group Inc
MDXG
▲ PositiveCapitalrelevance

Acquiring Sanara MedTech with cash and stock, strategic expansion.

Carbon Removal (DAC)▲ · 1 stocks
Aerospace & Aviation▲ · 1 stocks
Luxfer Holdings PLC
LXFR
▲ PositiveCapitalrelevance

Acquisition at $17.37 per share in cash, providing value to shareholders.

Financials▲ · 1 stocks
Aging Population▲ · 1 stocks
Sanara Medtech Inc
SMTI
± MixedCapitalrelevance

Acquisition by MiMedx at $33 cash plus shares; investigation into potential fiduciary breaches may affect deal terms.

Health Care▲ · 1 stocks
Artificial Intelligence▲ · 1 stocks
© 2026 MarketDXNews